Q1 Earnings Forecast for Nkarta Issued By HC Wainwright

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Nkarta in a research note issued to investors on Thursday, March 27th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.49) per share for the quarter. HC Wainwright has a "Buy" rating and a $18.00 price objective on the stock. The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta's Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS, FY2025 earnings at ($1.29) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.80) EPS and FY2028 earnings at ($1.54) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.06.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a "buy" rating and issued a $11.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, March 27th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $14.86.

Nkarta Stock Down 10.5 %

Shares of NASDAQ:NKTX traded down $0.20 during midday trading on Monday, reaching $1.71. The company's stock had a trading volume of 1,089,495 shares, compared to its average volume of 1,096,627. The firm has a 50 day moving average of $1.94 and a 200-day moving average of $2.75. The firm has a market capitalization of $121.34 million, a P/E ratio of -0.91 and a beta of 0.83. Nkarta has a 12-month low of $1.31 and a 12-month high of $10.16.

Institutional Investors Weigh In On Nkarta

Several hedge funds and other institutional investors have recently made changes to their positions in NKTX. Wells Fargo & Company MN grew its position in Nkarta by 27.8% during the fourth quarter. Wells Fargo & Company MN now owns 31,056 shares of the company's stock valued at $77,000 after buying an additional 6,763 shares during the period. Catalina Capital Group LLC grew its position in shares of Nkarta by 57.5% during the 4th quarter. Catalina Capital Group LLC now owns 18,818 shares of the company's stock valued at $47,000 after acquiring an additional 6,867 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company's stock worth $60,000 after purchasing an additional 7,030 shares in the last quarter. Erste Asset Management GmbH bought a new position in Nkarta in the 3rd quarter worth $33,000. Finally, American Century Companies Inc. raised its holdings in Nkarta by 8.8% in the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock worth $226,000 after purchasing an additional 7,378 shares during the period. Hedge funds and other institutional investors own 80.54% of the company's stock.

Insider Transactions at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total value of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares of the company's stock, valued at approximately $703,689.80. This represents a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.70% of the company's stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.